SHP099 HCl is primarily utilized in biomedical research as a potent and selective inhibitor of SHP2 phosphatase, an enzyme involved in various signaling pathways that regulate cell growth and differentiation. Its application is significant in the study of cancer, as SHP2 is often implicated in tumor progression and resistance to targeted therapies. Researchers use this compound to investigate the role of SHP2 in oncogenic signaling, particularly in cancers driven by mutations in RAS or receptor tyrosine kinases. Additionally, it serves as a tool to explore potential therapeutic strategies for diseases where SHP2 activity is dysregulated, such as certain types of leukemia and solid tumors. Its selectivity and efficacy make it a valuable compound for preclinical studies aimed at developing novel cancer treatments.